Flecainide

A 58-year-old man with lung cancer experienced various toxicities after starting treatment with erlotinib, including a grade 2 papulopustular rash, diarrhea, and late cutaneous adverse effects such as a mild, intermittent papulopustular rash, thicker and longer eyebrows, long and rigid eyelashes, telangiectasia, worsening of androgenetic alopecia, paronychia, conjunctivitis sicca, and dry skin. Despite these side effects, the treatment with erlotinib was continued at the same dosage, and the man's rash and diarrhea improved with treatment. At the time of the last follow-up, he had been receiving erlotinib for 38 months, although the outcome of the adverse reactions was not stated.